How would you approach a patient with a HER2+ locoregional recurrence who did not receive prior systemic therapy?
Patient only had upfront surgery.
Answer from: Medical Oncologist at Academic Institution
For a patient with an isolated, small in-breast recurrence, I would consider this a marker of a higher risk of distant recurrence and would give systemic adjuvant therapy, but would limit treatment to weekly paclitaxel and trastuzumab, since this is less toxic than the more aggressive regimens and h...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
If restaging was negative for mets, I would clip the recurrent mass and treat with neoadjuvant systemic therapy TCHP or ACTHP, resect, radiate, decide on adjuvant therapy w more HP or TDM1 +/- endocrine, as indicated based on response.